BioPharm International - February 2020

BioPharm-Outsourcing eBook

Issue link:

Contents of this Issue


Page 7 of 29

8 BioPharm International eBook February 2020 Sourcing Success in Cell and Gene Therapy Development As cell and gene therapies become more prominent, industry is seeking the expertise and capabilities of outsourcing partners to ensure success. A s cell and gene therapies are garnering more interest within the biopharma industry, demand for adequate manu- facturing capacity and talent to ensure success is increasing. To explore how outsourcing can prove beneficial for cell and gene therapy (CGT) development, BioPharm International spoke with Miguel Forte, chief commercialization officer, ISCT, CEO of Bone Therapeutics, and for- me r C E O of Z e l lu n a I m mu not he r apy ; A le ngo Nya may 'a nt u, sc ient i f ic com mu n icat ions ma n- ager, Polyplus-transfection; and Matthew Lakelin, vice-president business development and scientific affairs, TrakCel. KEY BENEFITS BioPharm: What are the key benefits of partnering with an outsourcing organization for the development of CGT? Forte (Bone Therapeutics): Outsourcing is a key element of any biotech business and virtually a requirement to be able to expand and reach out to needed competencies and resource management. For any biotech, and in particular for CGT highly innovative processes, the use of outsourcing enables companies to take advantage of additional required competencies. Even though the ownership of intellectual property (IP), know-how and processes, and data should always remain with the CGT companies, the ability to use outsourced competencies, in a field where not enough talent is available, is a very important success factor. In nobeastsofierce - FELICITY THOMAS Partnerships for Outsourcing Development

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm International - February 2020 - BioPharm-Outsourcing eBook